Novel Microbial-Based Immunotherapy Approach for Crohn's Disease.

Area of Science:

• Immunotherapy
• Gastroenterology
• Microbiome research

Background:

• Current Crohn's disease (CD) treatments suppress immunity, risking infection and cancer, yet often fail to halt disease progression.
• A need exists for novel CD therapies that improve patient outcomes by restoring immune function.
• QBECO, a microbial-derived immunotherapy, is being investigated as a new approach.

Purpose of the Study:

• To evaluate the safety, efficacy, and tolerability of QBECO in patients with moderate-to-severe CD.
• To assess QBECO's potential to restore immune function, unlike current immunosuppressive therapies.
• To explore immune biomarkers and genetic factors influencing QBECO response.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 68 moderate-to-severe CD patients.
• Primary endpoints included safety and clinical improvement at Week 8.
• Secondary endpoints assessed clinical response and remission at Week 8, with extended treatment for responders and non-responders.

Main Results:

• QBECO demonstrated good tolerability.
• Significant mean reduction in Crohn's Disease Activity Index (CDAI) score at Week 8 (-68 for QBECO vs. -31 for placebo), with continued improvement to Week 16 (-130 CDAI reduction).
• Week 8 clinical response, improvement, and remission rates were higher with QBECO (41.2%, 32.4%, 29.4%) compared to placebo (26.5%, 23.5%, 23.5%). Higher response rates (64%) were observed in TNFα inhibitor-naïve patients treated with QBECO.

Conclusions:

• This proof-of-concept study supports QBECO as a potential novel immunotherapy for CD.
• Biomarker analysis suggests personalized treatment strategies with QBECO may be feasible.
• Larger clinical trials are warranted to confirm these findings and explore biological mechanisms.